Key Takeaway
Retatrutide is expected to cost between $1,000 and $1,500 per month at list price, based on the pricing of similar GLP-1 medications. Final pricing hasn't been announced by Eli Lilly.
Retatrutide is expected to cost between $1,000 and $1,500 per month at list price, based on the pricing patterns of comparable GLP-1 and incretin-based medications. Eli Lilly hasn't announced official pricing because retatrutide hasn't yet received FDA approval. Actual out-of-pocket costs will depend on insurance coverage, discount programs, and pharmacy type.
Detailed Explanation
While no official price has been set, market analysts project retatrutide's cost by looking at Eli Lilly's existing weight loss drug, Zepbound (tirzepatide), and competing products like Wegovy (semaglutide). These medications currently carry list prices ranging from approximately $1,000 to $1,350 per month.
Retatrutide targets three hormone receptors (GLP-1, GIP, and glucagon) compared to the two receptors targeted by tirzepatide. This added mechanism of action could justify a premium price point. But competitive pressure from the growing number of obesity drugs in the pipeline may temper pricing.
Factors That Will Influence the Final Price
Several variables will determine what patients actually pay. Eli Lilly's pricing strategy will account for the competitive space at the time of launch. If multiple new obesity drugs reach market around the same time, pricing competition could push costs lower than current GLP-1 medications.
Insurance negotiations with pharmacy benefit managers (PBMs) will set the net price that health plans pay. The gap between list price and net price for GLP-1 drugs has historically been significant, with rebates sometimes exceeding 50% of the list price.
Patient assistance programs, manufacturer coupons, and savings cards could reduce out-of-pocket costs for eligible patients. Eli Lilly has offered such programs for Zepbound and Mounjaro, and a similar approach is expected for retatrutide.
How Current GLP-1 Costs Compare
For reference, the current monthly list prices for popular weight loss medications are approximately: Wegovy (semaglutide) at $1,350, Zepbound (tirzepatide) at $1,060, and Saxenda (liraglutide) at $1,350. After insurance or discount programs, many patients pay significantly less. Compounded GLP-1 and peptide therapy through telehealth providers like FormBlends can offer more affordable access to physician-supervised treatment.
What to Consider
- List price isn't what most patients pay. Insurance coverage, copay cards, and patient assistance programs can dramatically reduce the monthly cost.
- Insurance coverage isn't guaranteed. Many insurers still restrict or exclude weight loss medications. Coverage decisions for retatrutide will be made after FDA approval.
- Affordable options exist today. Physician-supervised telehealth programs offer GLP-1 and peptide therapy at lower price points than brand-name medications at retail pharmacies.
- Cost should include medical oversight. The price of safe, effective treatment includes provider consultations, lab monitoring, and dosage adjustments, not just the medication itself.
- Pricing may shift before launch. The obesity drug market is evolving rapidly, and competitive dynamics could change significantly by the time retatrutide reaches pharmacies.
Related Questions
Frequently Asked Questions
How does retatrutide differ from semaglutide and tirzepatide?
Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, compared to semaglutide (GLP-1 only) and tirzepatide (GLP-1 and GIP). This triple mechanism showed higher average weight loss in early clinical trials.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for physician-supervised GLP-1 therapy.
Try the BMI Calculator →View data table
| Category | Mean Body Weight Loss (%) | Detail |
|---|---|---|
| Placebo | 2 | ~2% weight loss |
| 4 mg | 17 | ~17% at 48 weeks |
| 8 mg | 22 | ~22% at 48 weeks |
| 12 mg | 24 | ~24% at 48 weeks |
What weight loss results has retatrutide shown in trials?
Phase 2 trial data published in the New England Journal of Medicine showed participants lost up to 24.2% of body weight at the highest dose over 48 weeks[1]. Phase 3 trials are evaluating these results in larger, more diverse patient populations.
When will retatrutide be available?
Retatrutide is currently in Phase 3 clinical trials. If trial results are positive, Eli Lilly could submit for FDA approval as early as 2025-2026, with potential commercial availability following approval. Timelines are subject to change based on regulatory review.
Medical References
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. [PubMed | ClinicalTrials.gov | DOI]
Take the Next Step
Effective weight loss treatment doesn't have to break the bank or wait for a future drug launch. FormBlends offers physician-supervised GLP-1 and peptide therapy at accessible price points through a simple telehealth process. Start your free consultation to find a treatment plan that fits your budget and goals.